Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

manilatimes.net · 2026-09-14

- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis

TickrTrends take: Ascendis Pharma announced it will regain rights to its TransCon technology platform in the metabolic and cardiovascular disease areas, representing a significant shift in the company's asset portfolio and strategic focus. This development carries implications for how investors should assess the company's future revenue potential and pipeline value, particularly as the healthcare sector increasingly prioritizes treatments for metabolic and cardiovascular conditions. As TickrTrends awaits full valuation data on ASND, the recovery of these rights adds a material element to the company's long-term asset base that will need to be factored into any comprehensive valuation analysis.

Read the full story at manilatimes.net →